ClinicalTrials.gg
RecruitingNCT07946991PROFIBREUpdated Nov 18, 2026

Protein and Fibre Impact on Human Surrogate Markers of Health

An interventional study of Isolated pea protein + high pea dietary fibre and Isolated pea protein + low pea dietary fibre in Healhty, sponsored by Örebro University, Sweden. Recruiting at 1 site in Sweden. Open to participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Örebro University, Sweden · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Study summary

A cross-over dietary intervention study with healthy participants (age 50-70 years old) will be conducted. Participants will receive plant-based protein-rich snacks with high or low dietary fibre content for 4 weeks. The goal of this project is to evaluate the impact of pea protein in combination with lower or higher dietary fibre intake on surrogate markers of metabolic, gut, and mental health.

Read the detailed description

The cross-over dietary intervention study will last 16 weeks and comprises 14 study visits, along with 2 screening visits to assess participant eligibility. Participants will be selected based on their Prevotella-to-Bacteroides ratio (high or low) and randomly assigned to one of the intervention arms. Throughout the study, blood, urine, stool, and exhaled breath samples will be collected. Body measurements will be obtained, and functional magnetic resonance imaging (fMRI) scans of the brain will be conducted. Data about food habits, physical activity, gastrointestinal symptoms, stool frequency and consistency, will be collected weekly using designated questionnaires. Questionnaires evaluating sleep, perceived stress as well as anxiety and depression will be collected at each fMRI visit. Participants will receive protein-rich snacks with high or low dietary fibre content during the two 4-week intervention periods (cross-over design). The snacks are plant-based, have a high protein content and different amounts of dietary fiber. After the 1st intervention phase participants will enter a minimum 4-week wash-out period with no intervention or questionnaires before starting the 2nd intervention phase. Considering the protein provided by both the habitual diet and the study products, participants are expected to consume more than 1.4 g of protein per kilogram of body weight per day. For dietary fibre intake, individuals with a habitual intake of 15 to 25 g per day will be eligible for inclusion. Consequently, the lower-fibre study product is expected to increase total fibre intake to approximately the recommended minimum level of 30 g per day, whereas the higher-fibre study product is anticipated to result in a substantially greater fibre intake.

02

Conditions studied

  • Healhty

Keywords

  • plant-based protein
  • dietary fibre
  • gut health
  • metabolic health
  • microbiota
03

In context

Lead sponsor

Örebro University, Sweden is the lead sponsor of 87 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 50-70 years old
  2. (BMI) 18,5-32 kg/m2
  3. Body weight of 50-90 kg
  4. Weight stable within the previous 3 months
  5. Maintenance of the usual physical activity habits during the study
  6. Prevotella and Bacteroides profile determined by qPCR.

Exclusion criteria

Exclusion Criteria:

  1. Acute chronic disease, inflammatory or functional gastrointestinal diseases and any other disease or disorder that could affect the outcome of the study
  2. Use of a medication that may interfere the study outcome
  3. Eating disorder
  4. Being vegan
  5. Usage of protein supplements during the study, including protein bars or protein enriched foods
  6. Usage of fibre supplements or high intake of food groups/ingredients that could affect the outcome of the study
  7. High protein intake
  8. Use of antibiotic medication during the last 3 months prior the first visit
  9. Trying to lose weight
  10. Trying to gain muscle mass
  11. Use of laxative or anti-diarrhoea medication within the past 3 months before the study
  12. Regular consumption of probiotic or prebiotic product for the past 6 weeks before the study
  13. Special diet that is considered to affect the study participation and/or study results, for example, high protein diets
  14. More than 5 h of moderate-vigorous exercise per week
  15. Intolerance to dietary supplements that will be used in the study
  16. Smoking
  17. Drinks more than 9 standard cups of alcohol per week and/or more than 3 standard cups alcohol per occasion
  18. Cerebral bleeding or history of cerebral bleeding
  19. Claustrophobia
  20. Inability to lay still for a longer time (e.g., due to tremor)
  21. In operated apparatus (e.g., pacemaker), as it interferes with MR imaging
  22. Aneurysm clips in the head
  23. Shunts in the head
  24. Grenade-splinter or metal-splinter in the body (e.g., eyes)
  25. Metal or electrodes in the body (e.g., temp-catheter, aorta stent, cochlea implant)
  26. Comprehensive tooth implants or prosthesis aa. Operated in the head bb. Operated in the heart cc. Swallowed a video-capsule, which may still be in the GI tract
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm A: High-low

    Participants will receive protein-rich snacks with a high dietary fibre content for 4 weeks, followed by a 4-week washout period and then 4 weeks of protein-rich snacks with a low dietary fibre content.

    Dietary Supplement: Isolated pea protein + high pea dietary fibre · Dietary Supplement: Isolated pea protein + low pea dietary fibre

  • Experimental
    Arm B: Low-high

    Participants will receive protein-rich snacks with a low dietary fibre content for 4 weeks, followed by a 4-week washout period and then 4 weeks of protein-rich snacks with a high dietary fibre content.

    Dietary Supplement: Isolated pea protein + high pea dietary fibre · Dietary Supplement: Isolated pea protein + low pea dietary fibre

Interventions

  • Dietary supplementIsolated pea protein + high pea dietary fibre

    Participants will receive a protein-rich snack with high dietary fibre content for 4 weeks as follows: * Protein in g/day from the snack: up to 40 g. * Dietary fibre g/day from the snack: up to 22 g. Participants will consume the intervention snack products for up to 3 times a day while maintaining an isocaloric diet and keeping the diet from the run-in period.

  • Dietary supplementIsolated pea protein + low pea dietary fibre

    Participants will receive a protein-rich snack with low dietary fibre content for 4 weeks as follows: * Protein in g/day from the snack: up to 40 g. * Dietary fibre g/day from the snack: up to 6 g. Participants will consume the intervention snack products for up to 3 times a day while maintaining an isocaloric diet and keeping the diet from the run-in period.

06

What researchers measure

Primary outcomes

  1. Microbial metabolites in feces (Targeted metabolomics)

    To evaluate the interaction between microbiota enterotypes (Prevotella vs. Bacteroides) and a higher-protein diet containing distinct amounts of dietary fibre on microbial metabolites in feces, including propionate, butyrate, acetate, valerate, isovalerate, isobutyrate, indole-3-butyrate, indole-3-propionate, and indole-3-acetate.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

Secondary outcomes

  1. Microbial metabolites in plasma (Targeted metabolomics)

    To evaluate the interaction between microbiota enterotypes (Prevotella vs. Bacteroides) and a higher-protein diet containing distinct amounts of dietary fibre on microbial metabolites in plasma, including propionate, butyrate, acetate, valerate, isovalerate, isobutyrate, indole-3-butyrate, indole-3-propionate, and indole-3-acetate in their native or metabolised forms.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

  2. Faecal metabolomics (gut-derived or endogenous metabolites)

    To determine whether the intervention and microbiota enterotypes influence other classes of gut-derived or endogenous metabolites, including carnitines, fatty acids, glycerolipids and phospholipids, sphingolipids, sterol and prenol lipids, amino acids, sugars, and other organic acids will be measured in feces.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

  3. Plasma metabolomics (gut-derived or endogenous metabolites)

    To determine whether the intervention and microbiota enterotypes influence other classes of gut-derived or endogenous metabolites, including carnitines, fatty acids, glycerolipids and phospholipids, sphingolipids, sterol and prenol lipids, amino acids, sugars, and other organic acids will be measured in plasma.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

  4. Faecal microbiota profiling

    To determine whether the intervention affected microbiota composition and function, faeces samples will be analysed by shotgun metagenomics, next-generation-sequencing (NGS) or by Illumina 16S rRNA amplicon sequencing, to produce relative abundance information for all genes, functions and organisms for a precise strain-level and functional annotation of the microbiome.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

Other outcomes

  1. Gut health status - Bristol Stool Scale

    To asses whether the intervention and the microbiota enterotype had an effect on the colonic transit time, The Bristol Stool Scale (BSS) diary will be used. Participants will receive a diary to fill in the frequency of evacuation and consistency of the faeces. The BSS is a validated 7-point visual and descriptive ordinal scale used to classify the consistency of human feces. Scores range from Type 1 (separate hard lumps, indicating constipation) to Type 7 (watery, entirely liquid stool, indicating diarrhea), where Types 3 and 4 represent normal stool consistency.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 14 scheduled study visits across two intervention periods separated by a 4-week washout period.

  2. Gut health status - The Gastrointestinal Symptom Rating Scale

    To asses whether the intervention and the microbiota enterotypes had an effect on gastrointestinal symptoms, The Gastrointestinal Symptom Rating Scale (GSRS) will be used. The rating scale consists of 15 items, evaluating gastrointestinal symptoms across 5 subscales: Reflux (2 items), Abdominal Pain (3 items), Indigestion (4 items), Diarrhea (3 items), and Constipation (3 items). Each item is rated on a 7-point Likert scale ranging from 1 (no symptoms) to 7 (severe symptoms). Domain scores are calculated as the average of the items within that domain, yielding a score range of 1 to 7 per subscale, where higher scores indicate greater symptom severity.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 14 scheduled study visits across two intervention periods separated by a 4-week washout period.

  3. Concentration of faecal calprotectin

    To asses whether the intervention and the microbiota enterotypes had an effect on gut inflammation, calprotectin will be measured in the participant's faeces as a surrogate health marker for gut inflammation.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 7 scheduled study visits across two intervention periods separated by a 4-week washout period.

  4. Inter-individual glucose response profiles

    To asses whether the intervention and the microbiota enterotypes had an effect on glucose levels via continuous glucose monitoring (CGM).

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 2 scheduled study visits across two intervention periods separated by a 4-week washout period (from visit 4 onwards for max. 14 days, and from visit 11 onwards for max. 14 days).

  5. Breath metabolomics

    Screening to explore potential associations with gut-related function.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

  6. Urine metabolomics

    Urine samples will be analysed using targeted and untargeted metabolomics

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

  7. Urine clinical markers for protein intake compliance

    Urine samples will be used to measure clinical markers of protein intake compliance (urea, creatine, and creatinine)

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

  8. Blood clinical markers for protein intake compliance

    Blood samples will be used to measure clinical markers of protein intake compliance (urea, creatine, and creatinine)

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

  9. Resting-state brain activity and structure

    To investigate whether the intervention affects resting-state brain activity and structure using functional MRI (fMRI)

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

  10. Mental health status - perceived stress

    Stress will be evaluated using the Perceived Stress Scale (PSS). This scale is a 10-item self-report questionnaire assessing the degree to which life situations over the past month are appraised as stressful, unpredictable, or uncontrollable. Each item is scored on a 5-point Likert scale ranging from 0 (never) to 4 (very often), with positive items reverse-scored. Items are summed to yield a single total score ranging from 0 to 40, where higher scores indicate greater levels of perceived stress (0-13: Low stress; 14-26: Moderate stress; 27-40: High perceived stress).

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

  11. Mental Health status - Sleep quality

    To assess sleep quality over the period of the intervention we will use the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-administered questionnaire. The items are combined to generate 7 component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction), each rated from 0 to 3, yielding a single global score ranging from 0 to 21, where higher scores indicate worse sleep quality (a global score greater than 5 indicates severe difficulties in at least two components).

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

  12. Mental health status - depression and anxiety

    Symptoms of depression and anxiety will be evaluated using the Hospital Anxiety and Depression Scale (HADS40). HADS40 is a 14-item self-rating questionnaire divided into two 7-item subscales: Anxiety (HADS-A) and Depression (HADS-D). Each item is scored from 0 to 3, yielding a final score range of 0 to 21 for each subscale, where higher scores indicate greater symptom severity (0-7: Normal; 8-10: Borderline abnormal; 11-21: Abnormal).

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

  13. Dried blood spots microbial metabolite analyses

    Capillary blood samples will be collected using dried blood spot cards to optimize a simpler protocol for metabolomic analysis, to facilitate sample handling and enable more efficient analyses in future studies.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

  14. Physical activity

    Participants will fill in the International Physical Activity Questionnaire (IPAQ) for monitoring physical activity and inactivity. The IPAQ is a 7-item self-report survey used to record the frequency and duration of walking, moderate-intensity, and vigorous-intensity physical activities over the previous 7 days. According to the official IPAQ scoring protocol, responses are weighted by energy requirements to calculate a weekly total physical activity volume expressed in Metabolic Equivalent of Task (MET)-minutes per week (walking = 3.3 METs, moderate activity = 4.0 METs, vigorous activity = 8.0 METs), where higher MET-minute values reflect greater energy expenditure and overall physical activity.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 14 scheduled study visits across two intervention periods separated by a 4-week washout period.

  15. Fasting blood glucose level

    Measurement of glucose in blood samples

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

  16. Fasting blood insulin level

    Measurement of insulin in blood samples

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

  17. Fasting blood C-reactive protein level

    Measurement of C-reactive protein in blood samples

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

  18. Fasting blood cholesterol (total, LDL, and HDL) level

    Measurement of cholesterol (total, LDL, and HDL) in blood samples (fasting state)

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

  19. Fasting blood triglycerides level

    Measurement of triglycerides in blood samples (fasting state)

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

  20. Blood Insulin-like growth factor 1 (IGF-1) level

    Measurement of insulin-like growth factor 1 in blood samples

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

  21. Height

    The height will be assessed in centimeters

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

  22. Body weight

    Participants will be weighted in order to have information of their body weight changes in kilograms during the study.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

  23. Body mass index

    Body mass index will be calculated: BMI=weight (kg)/height (m2)

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

  24. Homeostatic Model Assessment for Insulin Resistance (HOMA_IR)

    The HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) index will be calculated to measure insulin resistance.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

  25. Triglyceride glucose (TyG)

    Triglyceride glucose (TyG) index will be calculated to measure insulin resistance.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

  26. Dietary pattern

    The dietary pattern will be assessed through food diaries accompanied by a portion guide document.

    Time frame: From enrollment through study completion (up to 16 weeks) across two intervention periods separated by a 4-week washout period; 3 days a week, every week (except the washout period)

  27. Food Frequency Questionnaire

    The food diaries will be combined with a Food Frequency Questionnaire (FFQ).

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

  28. Body composition using bioelectrical impedance analysis (BIA) - weight

    Participants will be have their body weight (kg) measured using Tanita® full body scale.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

  29. BIA - muscle mass

    Participants will be have their body muscle mass (% and kg) measured using Tanita® full body scale.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

  30. BIA - body water content

    Participants will be have their body water content (% and kg) measured using Tanita® full body scale.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

  31. BIA - fat mass

    Participants will be have their body fat mass (% and kg) measured using Tanita® full body scale.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

  32. BIA - basal energy expenditure

    Participants will be have their basal energy expenditure (kcal and kJ) measured using Tanita® full body scale.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

  33. BIA - BMI

    Participants will be have their BMI in kg/m\^2. measured using Tanita® full body scale.

    Time frame: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Nov 18, 2026
StartActual
Sep 24, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946991
Lead sponsor
Örebro University, Sweden
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Sep 24, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Robert Brummer, PhD
Contact
robert.brummer@oru.se
004619303731
Tatiana M Marques, PhD
Contact
Tatiana.marques@oru.se
004619303308

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion